Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

IMPORTANCE: Based on contemporary estimates in the US, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To determine the use of evidence-based cardiovascular preventiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Adam J., O’Brien, Emily C., Kaltenbach, Lisa A., Green, Jennifer B., Lopes, Renato D., Morse, Caryn G., Al-Khalidi, Hussein R., Aroda, Vanita R., Cavender, Matthew A., Gaynor, Tanya, Kirk, Julienne K., Lingvay, Ildiko, Magwire, Melissa L., McGuire, Darren K., Pak, Jonathan, Pop-Busui, Rodica, Richardson, Caroline R., Senyucel, Cagri, Kelsey, Michelle D., Pagidipati, Neha J., Granger, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855234/
https://www.ncbi.nlm.nih.gov/pubmed/35175345
http://dx.doi.org/10.1001/jamanetworkopen.2021.48030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855234/
https://www.ncbi.nlm.nih.gov/pubmed/35175345
http://dx.doi.org/10.1001/jamanetworkopen.2021.48030

Ejemplares similares